Drug intelligence / Profile preview

SCT-01C

Development stage: Unknown
Lead developer: Sinocelltech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SCT-01C is a monoclonal antibody developed by Sinocelltech that targets the CD3 receptor on T-cells. It is designed for the treatment of various autoimmune diseases by modulating T-cell activity and potentially inducing immune tolerance. By binding to the CD3 epsilon subunit of the T-cell receptor complex, SCT-01C can inhibit the activation and proliferation of pathogenic T-cells that drive autoimmune responses. The drug is currently in Phase 1/2 clinical development, representing a targeted approach to managing immune-mediated conditions by regulating the immune system's cellular response.

Other names: CD3 antibodyCD-3 antibodyCD 3 antibodyCD3抗体

Targets

CD3E (T-cell surface glycoprotein CD3 epsilon chain)

Beyond the preview

Go deeper on SCT-01C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SCT-01C.

Explore the full profile